

MnVFC Announcement

Date: March 17, 2026
To: MnVFC Providers
From: MnVFC Program
Re: **MDH Extends Date for Use of RSV mAB Products**

Please route to:

- Clinical supervisor
- Medical director
- Clinic manager
- Clinic staff
- Pharmacy
- Vaccine staff

The Minnesota Department of Health (MDH) has extended the date for use of respiratory syncytial virus (RSV) monoclonal antibody (mAB) products through April 30. For more details review [Health Advisory: MDH Extends Date for Use of RSV Monoclonal Antibodies Through April 30, 2026](https://www.health.state.mn.us/communities/ep/han/2026/mar16rsv.pdf) (www.health.state.mn.us/communities/ep/han/2026/mar16rsv.pdf)

Both RSV monoclonal antibody (mAB) products, nirsevimab and clesrovimab, will remain available to order through the MnVFC program through April 2026. MnVFC providers can continue to place orders for both clesrovimab and nirsevimab in the regular order form in the Minnesota Immunization Information Connection (MIIC).

If needed, you may be able to continue to order RSV mAB products for your privately insured patients. Contact your vaccine manufacturer representatives or distributors accordingly. It is expected that commercial insurers will cover RSV-mAb products through April. Providers should verify coverage with individual plans if questions arise.

Maternal RSV vaccination ended in January, so you may see increased demand for mAB products among infants whose birthing parent did not have the opportunity to receive the vaccine during pregnancy.

MnVFC nirsevimab doses ordered now through April are short-dated and will expire in Aug./Sept. 2026. Consider your patient population and on-hand inventory when determining whether to place additional orders.

MnVFC Program
651-201-5522 or 1-800-657-3970
www.health.state.mn.us/vfc
health.mnvfc@state.mn.us